← back to search

Sebastian Schneeweiß

Harvard University · US
Area of research
Statistics and Probability · Economics and Econometrics
Research interest
His research is funded by multiple NIH, PCORI, BWF, and FDA grants and focuses on the comparative effectiveness and safety of biopharmaceuticals. He has developed analytic methods to improve the scientific validity of epidemiologic analyses using complex longitudinal healthcare databases particularly for newly marketed medical products. Applying such methods in rapid analysis cycles for sequential medication effectiveness monitoring and rapid response analyses is the overarching theme of his research. He is Aetion Inc.’s co-founder and Science Advisor were he develops a range of rapid-cycle analytics platforms for healthcare database networks around the world.
h-index
113
citations
49,727
works
804
NIH funding
primary concept
Medicine
email

Recent publications

Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET Statement
JAMA 2025cited by 106position: middledoi
Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA Sentinel Innovation Center
BMJ 2024cited by 52position: lastdoi
Measurement error and bias in real-world oncology endpoints when constructing external control arms
Frontiers in Drug Safety and Regulation 2024cited by 7position: middledoi
Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses
JAMA 2023cited by 367position: middledoi
Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease
Molecular Psychiatry 2022cited by 45position: middledoi
Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
Pharmacoepidemiology and Drug Safety 2022cited by 28position: middledoi
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>
Diabetes Obesity and Metabolism 2021cited by 39position: middledoi
Greedy caliper propensity score matching can yield variable estimates of the treatment‐outcome association—A simulation study
Pharmacoepidemiology and Drug Safety 2021cited by 20position: middledoi
Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results
Health Technology Assessment 2021cited by 5position: middledoi
Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes
JAMA Network Open 2020cited by 301position: lastdoi
Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials
European Respiratory Journal 2020cited by 22position: middledoi
Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution
Pharmacoepidemiology and Drug Safety 2019cited by 27position: middledoi
The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)
BMJ 2018cited by 608position: middledoi
Network-based approach to prediction and population-based validation of in silico drug repurposing
Nature Communications 2018cited by 564position: middledoi
Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study
The Journals of Gerontology Series A 2018cited by 261position: lastdoi
Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results
BMJ Open 2018cited by 11position: middledoi
Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index
The Journals of Gerontology Series A 2017cited by 591position: middledoi
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making
Value in Health 2017cited by 448position: middledoi
Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <scp>ISPOR‐ISPE</scp> Special Task Force on real‐world evidence in health care decision making
Pharmacoepidemiology and Drug Safety 2017cited by 341position: middledoi
Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records
Diabetes Obesity and Metabolism 2017cited by 79position: lastdoi
“Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
Clinical Pharmacology & Therapeutics 2016cited by 76position: middledoi
Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS): Architecture
Journal of the American Medical Informatics Association 2014cited by 95position: middledoi
Metrics for covariate balance in cohort studies of causal effects
Statistics in Medicine 2013cited by 317position: lastdoi
Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout
Arthritis Care & Research 2013cited by 31position: lastdoi
One‐to‐many propensity score matching in cohort studies
Pharmacoepidemiology and Drug Safety 2012cited by 515position: lastdoi
The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction
Pharmacoepidemiology and Drug Safety 2012cited by 287position: middledoi
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study
BMJ 2012cited by 268position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Shirley Wang · Array BioPharma (United States)7 papers (2017–2024)Rishi Desai · Harvard University5 papers (2018–2024)Liam Smeeth · Qatar University5 papers (2018–2022)Jessica M. Franklin · New England College of Optometry5 papers (2013–2023)Kevin Wing · Public Health Scotland4 papers (2018–2021)Elisabetta Patorno · Harvard University4 papers (2017–2024)Ian Douglas · London School of Hygiene & Tropical Medicine4 papers (2018–2022)Elizabeth Williamson · University of London4 papers (2018–2022) · 3 papers (2021–2024)Jennifer K Quint · Imperial College London3 papers (2018–2021)James R. Carpenter · London School of Hygiene & Tropical Medicine3 papers (2018–2021)Kenneth J. Rothman · Boston University3 papers (2012–2024)Lesley Wise · London School of Hygiene & Tropical Medicine3 papers (2018–2021)Kenneth Rockwood · Dalhousie University2 papers (2017–2018)Samy Suissa · McGill University Health Centre2 papers (2023–2024)Rosanna Tarricone · Yale Cancer Center2 papers (2017–2017)Sushama Kattinakere Sreedhara · Harvard University2 papers (2023–2024) · 2 papers (2017–2017)David Madigan · Columbia University2 papers (2017–2017)Wim Goettsch · Utrecht University2 papers (2017–2017)